GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » ROA %

LianBio (LianBio) ROA % : -35.50% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LianBio ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. LianBio's annualized Net Income for the quarter that ended in Sep. 2023 was $-96.16 Mil. LianBio's average Total Assets over the quarter that ended in Sep. 2023 was $270.85 Mil. Therefore, LianBio's annualized ROA % for the quarter that ended in Sep. 2023 was -35.50%.

The historical rank and industry rank for LianBio's ROA % or its related term are showing as below:

LIANY' s ROA % Range Over the Past 10 Years
Min: -86.4   Med: -55.64   Max: -29.02
Current: -29.02

During the past 4 years, LianBio's highest ROA % was -29.02%. The lowest was -86.40%. And the median was -55.64%.

LIANY's ROA % is ranked better than
55.26% of 1549 companies
in the Biotechnology industry
Industry Median: -34.69 vs LIANY: -29.02

LianBio ROA % Historical Data

The historical data trend for LianBio's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LianBio ROA % Chart

LianBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROA %
- -86.40 -55.64 -29.56

LianBio Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.21 -21.76 -30.90 -29.75 -35.50

Competitive Comparison of LianBio's ROA %

For the Biotechnology subindustry, LianBio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LianBio's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's ROA % distribution charts can be found below:

* The bar in red indicates where LianBio's ROA % falls into.



LianBio ROA % Calculation

LianBio's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-110.29/( (426.343+319.96)/ 2 )
=-110.29/373.1515
=-29.56 %

LianBio's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-96.156/( (278.798+262.902)/ 2 )
=-96.156/270.85
=-35.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


LianBio  (OTCPK:LIANY) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-96.156/270.85
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-96.156 / 0)*(0 / 270.85)
=Net Margin %*Asset Turnover
=N/A %*0
=-35.50 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


LianBio ROA % Related Terms

Thank you for viewing the detailed overview of LianBio's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


LianBio (LianBio) Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu officer: See Remarks C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn officer: Chief Business Officer C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang director, officer: Chief Executive Officer 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian officer: China General Manager C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304